Added receptor helps CAR T cells stay in bone marrow in cancer mouse models
By turning a patient's own immune cells into stronger cancer-fighting cells, CAR T-cell therapy has transformed how some blood cancers are treated. But it's been harder to extend this approach to solid tumors, including cancer that has spread to the bone.
Researchers have discovered a new way to bolster the effectiveness of CAR T-cell therapy for bone-metastatic cancers. By engineering gamma-delta T cells to produce a receptor that recognizes RANKL, a molecule prevalent in bone and tumor environments, these cells showed enhanced retention in the bone marrow. This improvement, detailed in a study published in Cellular and Molecular Immunology, suggests that modified gamma-delta CAR T cells could maintain their presence longer in patients with bone-metastatic solid tumors.
Written by urgent.news from Phys.org's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
